Merck buys Schering-Plough: first thoughts

More

So after weeks of rumors, Merck has decided to buy Schering-Plough. This ends two eras - the one where S-P was one of the last mid-sized pharmaceutical companies, and the one where Merck grew mostly from the inside. I have to say, I'm sorry to see the end of both. Drug discovery is risky and complicated, and it needs as many different viewpoints and shots on goal as possible. Big mergers like this don't help the industry's ecology much. Today's merger isn't as disturbing as the Blob-like growth of Pfizer, but it's still not happy news. (Full disclosure: I used to work at Schering-Plough in the 1990s - a few tales from that era can be found here and here).

Does this deal make sense?


If you think that big drug company mergers make sense, then I suppose it does. The two companies have Vytorin, the combination cholesterol drug that's not going to be make anyone as much money as it was supposed to. And Schering-Plough has a promising cardiovascular drug and some other programs that will fit reasonably well into Merck's portfolio. The two main R&D sites are within a few miles of each other in New Jersey, so it'll be interesting to see how the staffing and facilities issues eventually get resolved (there are supposed to be cost savings in that area, naturally).

I'm still not happy about this one, but I'm clearly out of step. I miss the days when large drug companies could keep themselves going with their own research programs. I worry about the vitality of research under the present conditions. And I wonder what happens when there aren't any more big mergers to be made.

Derek Lowe blogs from inside the drug labs at In the Pipeline.

Jump to comments
Presented by

Derek Lowe

Derek Lowe is a drug discovery chemist with 20 years of experience in the pharmaceutical industry, which is still very much his day job. He's worked on projects targeted at Alzheimer's, cancer, diabetes, infectious diseases, and other areas, but like most discovery scientists in the business, he has yet to produce a marketed drug. Explaining how and why this happens is what led to the launch of his blog, "In the Pipeline", in 2002, and the explaining continues. . .
Get Today's Top Stories in Your Inbox (preview)

Adventures in Legal Weed

Colorado is now well into its first year as the first state to legalize recreational marijuana. How's it going? James Hamblin visits Aspen.


Elsewhere on the web

Join the Discussion

After you comment, click Post. If you’re not already logged in you will be asked to log in or register. blog comments powered by Disqus

Video

Adventures in Legal Weed

Colorado is now well into its first year as the first state to legalize recreational marijuana. How's it going? James Hamblin visits Aspen.

Video

What Makes a Story Great?

The storytellers behind House of CardsandThis American Life reflect on the creative process.

Video

Tracing Sriracha's Origin to Thailand

Ever wonder how the wildly popular hot sauce got its name? It all started in Si Racha.

Video

Where Confiscated Wildlife Ends Up

A government facility outside of Denver houses more than a million products of the illegal wildlife trade, from tigers and bears to bald eagles.

Video

Is Wine Healthy?

James Hamblin prepares to impress his date with knowledge about the health benefits of wine.

Video

The World's Largest Balloon Festival

Nine days, more than 700 balloons, and a whole lot of hot air

Writers

Up
Down

More in Business

Just In